Skip to Content

Reports suggesting that CRISPR could cause cancer dinged the stock prices of the big three gene editing companies: Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics all fell by 10 percent or more.

The findings: CRISPR is all about cutting DNA—but cells don’t like that very much. Two papers in the journal Nature Medicine (here and here) found that the damage cause by CRISPR can kill cells or stop them from growing.

The problem: CRISPR is a lot less likely to kill cells with defective versions of a gene called p53, whose anticancer role has led some to call it the guardian of the genome. In short, CRISPR could give a survival advantage to cells likely to turn cancerous, according to Stat.

The upshot: The new findings could help explain why the U.S. Food & Drug Administration placed a planned human study by CRISPR Therapeutics on hold in May. That company has hoped to use CRISPR as a gene therapy to treat sickle-cell disease.

 

Deep Dive

Biotechnology

How scientists want to make you young again

Research labs are pursuing technology to “reprogram” aging bodies back to youth.

Human brain cells transplanted into baby rats’ brains grow and form connections

When lab-grown clumps of human neurons are transplanted into newborn rats, they grow with the animals. The research raises some tricky ethical questions.

Inside the billion-dollar meeting for the mega-rich who want to live forever

Hope, hype, and self-experimentation collided at an exclusive conference for ultra-rich investors who want to extend their lives past 100. I went along for the ride.

The debate over whether aging is a disease rages on

In its latest catalogue of health conditions, the World Health Organization almost equated old age with disease. Then it backed off.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.